Research programme: asthma/allergy therapy - Affimed Therapeutics

Drug Profile

Research programme: asthma/allergy therapy - Affimed Therapeutics

Alternative Names: AFM 19; anti IL-13R

Latest Information Update: 22 Jul 2010

Price : $50

At a glance

  • Originator Affimed Therapeutics
  • Class Antibodies
  • Mechanism of Action Interleukin 13 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Asthma; Hypersensitivity

Most Recent Events

  • 26 Jul 2005 Preclinical trials in Allergy in Germany (unspecified route)
  • 26 Jul 2005 Preclinical trials in Asthma in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top